Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 87Breast 39Sarcoma 33Other hematologic neoplasm 29CNS 18Gastrointestinal 16Gynecologic 13Plasma cell 10Thoracic 8Other solid neoplasm 7Genitourinary 7Myeloid 3Dermatologic 3Tumor-Agnostic 2Head & Neck 2Endocrine 2Classical hematology 1

Conditions

Neoplasms, Unknown Primary 1Neoplasm Metastasis 1

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Doxorubicin × Tumor-Agnostic × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00022178 2013-09-20

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

National Cancer Institute (NCI)

Phase 3 Unknown
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡